› Forums › General Melanoma Community › great news!
- This topic has 21 replies, 6 voices, and was last updated 12 years, 8 months ago by
jim Breitfeller.
- Post
-
- March 27, 2013 at 7:13 am
Hello,
Got great news today! Had previously a 1 cm tumor in y arm, 4.3 cm nodule in my lower left abdomen and 1.9 cm nodual in my upper left abdomen. As well as 7 mm and 2mm spots in my brain.
Found out today, both brain spots are gone, the arm tumor is gone, and both abdomen tumors are shrinking! best news I could have heard….
Hello,
Got great news today! Had previously a 1 cm tumor in y arm, 4.3 cm nodule in my lower left abdomen and 1.9 cm nodual in my upper left abdomen. As well as 7 mm and 2mm spots in my brain.
Found out today, both brain spots are gone, the arm tumor is gone, and both abdomen tumors are shrinking! best news I could have heard….
I am currently in a clinical trial at the Angeles Clinic in Los Angeles…Ipi and experimental pill. pill doesn't have a name just an bunch of letters and numbers lol. Its a new trial as I believe I was only the 2nd patient enrolled. I believe the ful name of my trial is on my profile.
Feeling very grateful today to say the least!
Jeff
- Replies
-
-
- March 27, 2013 at 11:11 am
Clinical Trial(s): A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic MelanomaCongrats Jeff!! I’m having my third dose of Ipilimumab next Tuesday and am hoping for good results. Have you had any side effects?
Holly
Ps – I grew up in Westlake 1970-1983. Neighbors!
-
- March 27, 2013 at 11:11 am
Clinical Trial(s): A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic MelanomaCongrats Jeff!! I’m having my third dose of Ipilimumab next Tuesday and am hoping for good results. Have you had any side effects?
Holly
Ps – I grew up in Westlake 1970-1983. Neighbors!
-
- March 28, 2013 at 6:30 am
Hi Holly,
yes that is the trial I am on!
Thank you! I hope the ipi is just as successful for you as it has been for me. I have had very minor side effects. Mainly fatigue, slight nausea. Oh and my mustache is coming in white now haha Definitly not complaining.
Are you just taking ipi or are you in a combination drug trail?
Jeff
-
- March 28, 2013 at 6:30 am
Hi Holly,
yes that is the trial I am on!
Thank you! I hope the ipi is just as successful for you as it has been for me. I have had very minor side effects. Mainly fatigue, slight nausea. Oh and my mustache is coming in white now haha Definitly not complaining.
Are you just taking ipi or are you in a combination drug trail?
Jeff
-
- March 28, 2013 at 6:30 am
Hi Holly,
yes that is the trial I am on!
Thank you! I hope the ipi is just as successful for you as it has been for me. I have had very minor side effects. Mainly fatigue, slight nausea. Oh and my mustache is coming in white now haha Definitly not complaining.
Are you just taking ipi or are you in a combination drug trail?
Jeff
-
- March 28, 2013 at 11:22 am
Just Ipilimumab right now. Keeping my fingers crossed for all of us!
Holly -
- March 28, 2013 at 11:22 am
Just Ipilimumab right now. Keeping my fingers crossed for all of us!
Holly -
- March 28, 2013 at 11:22 am
Just Ipilimumab right now. Keeping my fingers crossed for all of us!
Holly -
- March 28, 2013 at 1:36 pm
I haven’t heard of INCB024360– does this appear to have great promise? I see anti-PD-1 coupled with IPI in trials– does this compound have the same promise– perhaps representing another hope. I see current trials are restricted to those who haven’t been treated with anti-PD-1…. But I suppose there may eventually be trials that assess how these may compliment each other???? -
- March 28, 2013 at 1:36 pm
I haven’t heard of INCB024360– does this appear to have great promise? I see anti-PD-1 coupled with IPI in trials– does this compound have the same promise– perhaps representing another hope. I see current trials are restricted to those who haven’t been treated with anti-PD-1…. But I suppose there may eventually be trials that assess how these may compliment each other???? -
- March 28, 2013 at 1:36 pm
I haven’t heard of INCB024360– does this appear to have great promise? I see anti-PD-1 coupled with IPI in trials– does this compound have the same promise– perhaps representing another hope. I see current trials are restricted to those who haven’t been treated with anti-PD-1…. But I suppose there may eventually be trials that assess how these may compliment each other????
-
- March 27, 2013 at 11:11 am
Clinical Trial(s): A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic MelanomaCongrats Jeff!! I’m having my third dose of Ipilimumab next Tuesday and am hoping for good results. Have you had any side effects?
Holly
Ps – I grew up in Westlake 1970-1983. Neighbors!
-
- March 27, 2013 at 9:32 pm
Great news and thanks for sharing – we melanoma patients and caregivers
need all the encouragement we can get. Enjoy!!!!
-
- March 27, 2013 at 9:32 pm
Great news and thanks for sharing – we melanoma patients and caregivers
need all the encouragement we can get. Enjoy!!!!
-
- March 27, 2013 at 9:32 pm
Great news and thanks for sharing – we melanoma patients and caregivers
need all the encouragement we can get. Enjoy!!!!
-
- March 28, 2013 at 3:29 pm
Indoleamine 2,3-dioxygenase-1 (IDO1; IDO) mediates oxidative cleavage of tryptophan, an amino acid essential for cell proliferation and survival. IDO1 inhibition is proposed to have therapeutic potential in immunodeficiency-associated abnormalities, including cancer. Here, we describe INCB024360, a novel IDO1 inhibitor, and investigate its roles in regulating various immune cells and therapeutic potential as an anticancer agent. In cellular assays, INCB024360 selectively inhibits human IDO1 with IC50 values of approximately 10nM, demonstrating little activity against other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO). In coculture systems of human allogeneic lymphocytes with dendritic cells (DCs) or tumor cells, INCB024360 inhibition of IDO1 promotes T and natural killer (NK)–cell growth, increases IFN-γ production, and reduces conversion to regulatory T (Treg)–like cells. IDO1 induction triggers DC apoptosis, whereas INCB024360 reverses this and increases the number of CD86high DCs, potentially representing a novel mechanism by which IDO1 inhibition activates T cells. Furthermore, IDO1 regulation differs in DCs versus tumor cells. Consistent with its effects in vitro, administration of INCB024360 to tumor-bearing mice significantly inhibits tumor growth in a lymphocyte-dependent manner. Analysis of plasma kynurenine/tryptophan levels in patients with cancer affirms that the IDO pathway is activated in multiple tumor types. Collectively, the data suggest that selective inhibition of IDO1 may represent an attractive cancer therapeutic strategy via up-regulation of cellular immunity. -
- March 28, 2013 at 3:29 pm
Indoleamine 2,3-dioxygenase-1 (IDO1; IDO) mediates oxidative cleavage of tryptophan, an amino acid essential for cell proliferation and survival. IDO1 inhibition is proposed to have therapeutic potential in immunodeficiency-associated abnormalities, including cancer. Here, we describe INCB024360, a novel IDO1 inhibitor, and investigate its roles in regulating various immune cells and therapeutic potential as an anticancer agent. In cellular assays, INCB024360 selectively inhibits human IDO1 with IC50 values of approximately 10nM, demonstrating little activity against other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO). In coculture systems of human allogeneic lymphocytes with dendritic cells (DCs) or tumor cells, INCB024360 inhibition of IDO1 promotes T and natural killer (NK)–cell growth, increases IFN-γ production, and reduces conversion to regulatory T (Treg)–like cells. IDO1 induction triggers DC apoptosis, whereas INCB024360 reverses this and increases the number of CD86high DCs, potentially representing a novel mechanism by which IDO1 inhibition activates T cells. Furthermore, IDO1 regulation differs in DCs versus tumor cells. Consistent with its effects in vitro, administration of INCB024360 to tumor-bearing mice significantly inhibits tumor growth in a lymphocyte-dependent manner. Analysis of plasma kynurenine/tryptophan levels in patients with cancer affirms that the IDO pathway is activated in multiple tumor types. Collectively, the data suggest that selective inhibition of IDO1 may represent an attractive cancer therapeutic strategy via up-regulation of cellular immunity. -
- March 28, 2013 at 3:29 pm
Indoleamine 2,3-dioxygenase-1 (IDO1; IDO) mediates oxidative cleavage of tryptophan, an amino acid essential for cell proliferation and survival. IDO1 inhibition is proposed to have therapeutic potential in immunodeficiency-associated abnormalities, including cancer. Here, we describe INCB024360, a novel IDO1 inhibitor, and investigate its roles in regulating various immune cells and therapeutic potential as an anticancer agent. In cellular assays, INCB024360 selectively inhibits human IDO1 with IC50 values of approximately 10nM, demonstrating little activity against other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO). In coculture systems of human allogeneic lymphocytes with dendritic cells (DCs) or tumor cells, INCB024360 inhibition of IDO1 promotes T and natural killer (NK)–cell growth, increases IFN-γ production, and reduces conversion to regulatory T (Treg)–like cells. IDO1 induction triggers DC apoptosis, whereas INCB024360 reverses this and increases the number of CD86high DCs, potentially representing a novel mechanism by which IDO1 inhibition activates T cells. Furthermore, IDO1 regulation differs in DCs versus tumor cells. Consistent with its effects in vitro, administration of INCB024360 to tumor-bearing mice significantly inhibits tumor growth in a lymphocyte-dependent manner. Analysis of plasma kynurenine/tryptophan levels in patients with cancer affirms that the IDO pathway is activated in multiple tumor types. Collectively, the data suggest that selective inhibition of IDO1 may represent an attractive cancer therapeutic strategy via up-regulation of cellular immunity.
-
- You must be logged in to reply to this topic.